breast cancer – Page 4

Vepdegestrant: A Next-Generation Oral PROTAC ER Degrader for Advanced ER+/HER2– Breast Cancer—VERITAC-2 Results and Clinical Implications

By MedXY 08/07/2025

Vepdegestrant, an oral PROTAC estrogen receptor degrader, significantly prolongs progression-free survival compared to fulvestrant in ESR1-mutant advanced breast cancer, but not in the overall ER+/HER2– population.

Clinical Updates Oncology Specialties

No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial

By MedXY 08/07/2025

The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.

Clinical Updates news Oncology Specialties

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

By MedXY 08/05/2025

The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and manageable safety.

Family Medicine & Nutrition Medical News news Specialties

One Exercise Session Can Fight Cancer! Latest Study Confirms: These Two Exercise Types Instantly Produce Anti-Cancer Substances That Significantly Inhibit Cancer Cell Growth

By MedXY 08/04/2025

A single session of resistance or high-intensity interval training boosts anti-cancer myokines in breast cancer survivors, significantly suppressing cancer cell growth in vitro.

Clinical Updates news Oncology Specialties

Efficacy and Safety of 5 mg Olanzapine Added to Standard Antiemetics for Breast Cancer Chemotherapy: Insights from a Phase 3 Double-Blind Trial

By MedXY 08/02/2025

Adding 5 mg olanzapine after anthracycline-based chemotherapy significantly improves nausea and vomiting control with minimal sedation in breast cancer patients compared to standard antiemetic therapy alone.

Clinical Updates news Oncology Specialties

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

By MedXY 08/01/2025

A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.

Clinical Updates news Oncology Orthopedics Specialties

Inconsistent Bone Health Management in Older Women With Breast Cancer: Insights From the Age Gap Study

By MedXY 07/31/2025

Significant variation exists in bone health management for older women receiving endocrine therapy for breast cancer, highlighting the need for standardized care.

Clinical Updates news Oncology Specialties

Antibody-Drug Conjugates in Breast Cancer: Efficacy, Toxicity, and Evolving Management Strategies

By MedXY 07/30/2025

Antibody-drug conjugates (ADCs) have transformed breast cancer therapy but bring notable toxicity risks. This review examines the clinical evidence, adverse event management, and future directions for optimizing ADC use.

news OB/GYN & Women's Health Specialties

Removing Out-of-Pocket Costs Increases Access to 3D Mammograms

By MedXY 07/29/2025

Eliminating a $45 fee for advanced breast cancer screening technology improves access and reduces health disparities, according to recent research.

news OB/GYN & Women's Health Oncology Specialties

Understanding Hormone Therapy and Breast Cancer Risk in Younger Women

By MedXY 07/29/2025

Recent research highlights that estrogen-only hormone therapy may reduce breast cancer risk in women under 55, while combined estrogen-progestin therapy could increase risk.